Valerio Therapeutics : publishes its 2025 annual results and annual financial report, and confirms the strategic transformation of its operating model

About this update from Valerio Therapeutics

PreviousValerio Therapeutics publishes its 2025 annual results and annual financial report, and confirms the strategic transformation of its operating modelValerio Therapeutics publishes its 2025 annual results and annual financial report, and confirms the strategic transformation of its operating modelRevenue: €2.6 million for the 2025 financial year, compared with €1.8 million in 2024 Operating expenses: €4.8 million, compared with €18.3 million in 2024 Creation of InVimmune, the Group's first subsidiary in in vivo cell therapy, and execution of several partnership agreements during the financial year Villejuif, April 28, 2026 - Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the "Company"), today announces the publication of its annual results and annual financial report for the 2025 financial year, [available on its website under the "Financial Information" section], and outlines the key pillars of its strategic roadmap."2025 was a year of profound transformation for Valerio Therapeutics. We clarified our strategic direction, strengthened our scientific foundations and continued to validate our technology platforms. The Company's strategy is built around three pillars: internal programs, partnerships/licensing, and the creation of subsidiaries. Our first subsidiary, InVimmune, represents an important milestone and opens up highly attractive opportunities in indications with significant unmet medical needs. At the same time, we continue to strengthen our teams and reinforce our expertise in order to accelerate the development of our technology platforms and pipeline. We believe that our talents, together with the network of experts surrounding Valerio, will enable the Company to achieve its objectives," said Julien Miara, Chief Executive Officer of the Company. Strategic refocusing Following the structural transformation of its operating model initiated in 2025, aimed at refocusing its activities in order to concentrate its resources on preclinical opportunities with strong value-creation and partnership potential, the Company now focuses its efforts on the development of its proprietary V-Body and integrated chemistry platforms, which form the foundation of its next phase of growth. This strategic refocusing has tran...

View stock analysis, news, and events for Valerio Therapeutics